JNJ Stock Summary and Trading Ideas (Johnson & Johnson | NYSE:JNJ)

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.

As of March 13, 2026, JNJ stock price declined to $241.52 with 4,759,260 million shares trading.

JNJ has a beta of 0.21, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.04 to the broad based SPY ETF.

JNJ has a market cap of $581.58 billion. This is considered a Mega Cap stock.

Last quarter Johnson & Johnson reported $25 billion in Revenue and $2.46 earnings per share. This beat revenue expectation by $414 million and missed earnings estimates by -$.01.

In the last 3 years, JNJ traded as high as $251.71 and as low as $140.68.

The top ETF exchange traded funds that JNJ belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.

JNJ has outperformed the market in the last year with a price return of +51.4% while the SPY ETF gained +21.4%. JNJ has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +14.8% and -2.8%, respectively, while the SPY returned -2.6% and -3.5%, respectively.

JNJ support price is $239.26 and resistance is $244.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ shares will trade within this expected range on the day.